An ultrasensitive FEN1-aided LCR-electrochemical biosensor enables detection of BCR/ABL1 fusion transcripts in clinical samples for early diagnosis and minimal residual monitoring of CML

Key Points

• BCR/ABL1 fusion transcripts were detected with an ultrasensitive biosensor, facilitating early diagnosis.
• The biosensor achieved high specificity and sensitivity for clinical samples, allowing monitoring of minimal residual disease.
• Applications of the electrochemical biosensor include potential widespread implementation for chronic myeloid leukemia patients.
• Further validation in diverse clinical settings is essential to ascertain broader implications for CML management.